The Star Target in SLE: IL-17

Overview

Journal Inflamm Res

Specialties Allergy & Immunology
Pathology

Date 2022 Dec 20

PMID 36538077

Authors

Yi Yang

Chen Yan

Le Yu

Xiuling Zhang

JingJing Shang

Jie Fan

Rongwei Zhang

Jie Ren

Xinwang Duan

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this review is to discuss the significance of IL-17 in SLE and the potential of IL-17-targeted therapy.

Background: Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect many organs and tissues throughout the body. It is characterized by overactive B and T cells and loss of immune tolerance to autoantigens. Interleukin-17 (IL-17) is a cytokine that promotes inflammation and has been implicated in the pathogenesis of several autoimmune diseases as well as inflammatory diseases. In in vitro cellular experiments in lupus susceptible mice or SLE patients, there is substantial evidence that IL-17 is a highly promising therapeutic target.

Methods: We searched papers from PubMed database using the search terms, such as interleukin-17, systemic lupus erythematosus, treatment targets, T cells, lupus nephritis, and other relevant terms.

Results: We discuss in this paper the molecular mechanisms of IL-17 expression, Th17 cell proliferation, and the relationship between IL-17 and Th17. The significance of IL-17 in SLE and the potential of IL-17-targeted therapy are further discussed in detail.

Conclusion: IL-17 has a very high potential for the development as a star target in SLE.

Citing Articles

Soluble CD72, is a T-cell activator probably via binding to CD6 in homeostasis and autoimmunity.

Eiza N, Sabag A, Kessler O, Toubi E, Vadasz Z Front Immunol. 2024; 15:1367120.

PMID: 39026665 PMC: 11254670. DOI: 10.3389/fimmu.2024.1367120.

Evidence from mendelian randomization identifies several causal relationships between primary membranous nephropathy and gut microbiota.

Wu J, Zhang J, Huang G, Zhong Y, Yang Y, Deng P Ren Fail. 2024; 46(1):2349136.

PMID: 38770992 PMC: 11110878. DOI: 10.1080/0886022X.2024.2349136.

Integrative analysis of single-cell and bulk transcriptome data reveal the significant role of macrophages in lupus nephritis.

Wei S, Shen H, Zhang Y, Liu C, Li S, Yao J Arthritis Res Ther. 2024; 26(1):84.

PMID: 38610007 PMC: 11010324. DOI: 10.1186/s13075-024-03311-y.

Response of Psoriasis with Systemic Lupus Erythematosus to Secukinumab: A Case Report and Review of the Literature.

Dai B, Bai Y, Yu H, Huang Q, Wang L Clin Cosmet Investig Dermatol. 2023; 16:3589-3594.

PMID: 38116143 PMC: 10729829. DOI: 10.2147/CCID.S440977.

Characterization of Serum Cytokine Profiles of Patients with Active Lupus Nephritis.

Rahme Z, Franco C, Cruciani C, Pettorossi F, Zaramella A, Realdon S Int J Mol Sci. 2023; 24(19).

PMID: 37834330 PMC: 10573765. DOI: 10.3390/ijms241914883.

References

Lim S, Helmick C, Bao G, Hootman J, Bayakly R, Gordon C . Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus - Fulton and DeKalb Counties, Georgia, 2002-2016. MMWR Morb Mortal Wkly Rep. 2019; 68(18):419-422. PMC: 6542193. DOI: 10.15585/mmwr.mm6818a4. View

Fanouriakis A, Tziolos N, Bertsias G, Boumpas D . Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2020; 80(1):14-25. DOI: 10.1136/annrheumdis-2020-218272. View

Park H, Li Z, Yang X, Chang S, Nurieva R, Wang Y . A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005; 6(11):1133-41. PMC: 1618871. DOI: 10.1038/ni1261. View

Harrington L, Hatton R, Mangan P, Turner H, Murphy T, Murphy K . Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005; 6(11):1123-32. DOI: 10.1038/ni1254. View

Miossec P, Kolls J . Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012; 11(10):763-76. DOI: 10.1038/nrd3794. View

Burkett P, Meyer Zu Horste G, Kuchroo V . Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. J Clin Invest. 2015; 125(6):2211-9. PMC: 4497747. DOI: 10.1172/JCI78085. View

Amarilyo G, Lourenco E, Shi F, La Cava A . IL-17 promotes murine lupus. J Immunol. 2014; 193(2):540-3. DOI: 10.4049/jimmunol.1400931. View

Crispin J, Oukka M, Bayliss G, Cohen R, Van Beek C, Stillman I . Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol. 2008; 181(12):8761-6. PMC: 2596652. DOI: 10.4049/jimmunol.181.12.8761. View

Yao Z, Fanslow W, Seldin M, Rousseau A, Painter S, Comeau M . Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity. 1995; 3(6):811-21. DOI: 10.1016/1074-7613(95)90070-5. View

10.

Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H . Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017; 19(1):285. PMC: 5741872. DOI: 10.1186/s13075-017-1490-y. View

11.

Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P . Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015; 373(26):2534-48. DOI: 10.1056/NEJMoa1505066. View

12.

Mease P, Genovese M, Greenwald M, Ritchlin C, Beaulieu A, Deodhar A . Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014; 370(24):2295-306. DOI: 10.1056/NEJMoa1315231. View

13.

Warren R, Blauvelt A, Bagel J, Papp K, Yamauchi P, Armstrong A . Bimekizumab versus Adalimumab in Plaque Psoriasis. N Engl J Med. 2021; 385(2):130-141. DOI: 10.1056/NEJMoa2102388. View

14.

Reich K, Warren R, Lebwohl M, Gooderham M, Strober B, Langley R . Bimekizumab versus Secukinumab in Plaque Psoriasis. N Engl J Med. 2021; 385(2):142-152. DOI: 10.1056/NEJMoa2102383. View

15.

Langley R, Elewski B, Lebwohl M, Reich K, Griffiths C, Papp K . Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014; 371(4):326-38. DOI: 10.1056/NEJMoa1314258. View

16.

Rafael-Vidal C, Perez N, Altabas I, Garcia S, Pego-Reigosa J . Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases. Int J Mol Sci. 2020; 21(19). PMC: 7582977. DOI: 10.3390/ijms21197100. View

17.

Jakiela B, Kosalka J, Plutecka H, Bazan-Socha S, Sanak M, Musial J . Facilitated expansion of Th17 cells in lupus nephritis patients. Clin Exp Immunol. 2018; 194(3):283-294. PMC: 6230997. DOI: 10.1111/cei.13196. View

18.

Stadhouders R, Lubberts E, Hendriks R . A cellular and molecular view of T helper 17 cell plasticity in autoimmunity. J Autoimmun. 2017; 87:1-15. DOI: 10.1016/j.jaut.2017.12.007. View

19.

Koga T, Ichinose K, Tsokos G . T cells and IL-17 in lupus nephritis. Clin Immunol. 2016; 185:95-99. PMC: 5074925. DOI: 10.1016/j.clim.2016.04.010. View

20.

Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X . Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009; 60(5):1472-83. DOI: 10.1002/art.24499. View